Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Oct 2014 07:00 AM
RNS
Final Results
30 Sep 2014 07:00 AM
RNS
Affimer On-line Catalogue Launch
29 Sep 2014 07:00 AM
RNS
Investor Briefing
22 Sep 2014 07:00 AM
RNS
Appointment of a Senior Executive
04 Aug 2014 07:00 AM
RNS
New OPTIM Software and Hardware
01 Aug 2014 07:00 AM
RNS
Pre Close Trading Update
15 Jul 2014 07:00 AM
RNS
Major Japanese Distributor Signed
13 Jun 2014 11:04 AM
RNS
Holding(s) in Company
02 Jun 2014 01:04 PM
RNS
Holding(s) in Company
02 Jun 2014 07:00 AM
RNS
Avacta Secures Funding Award
30 May 2014 04:37 PM
RNS
Holding(s) in Company
30 May 2014 02:52 PM
RNS
Holding(s) in Company
29 May 2014 04:21 PM
RNS
Holding(s) in Company
28 May 2014 07:00 AM
RNS
Avacta Life Sciences Exhibits Affimers at PEGS
23 May 2014 12:53 PM
RNS
Result of General Meeting
21 May 2014 05:36 PM
RNS
Holding(s) in Company
14 May 2014 07:00 AM
RNS
Issue of Equity
09 May 2014 04:19 PM
RNS
Director's dealing
09 May 2014 07:00 AM
RNS
Avacta Announce Collaboration with UbiQ Bio BV
07 May 2014 07:00 AM
RNS
Conditional Placing
23 Apr 2014 07:00 AM
RNS
Interim Results
14 Apr 2014 07:00 AM
RNS
Avacta Launch Pancreatitis Test for Dogs
20 Mar 2014 07:00 AM
RNS
Affimers : Technical and Commercial Update
11 Mar 2014 07:00 AM
RNS
Notice of Interim Results
24 Feb 2014 07:00 AM
RNS
Directors Dealings
05 Feb 2014 07:00 AM
RNS
New Board Appointment
04 Feb 2014 09:29 AM
RNS
Holding(s) in Company
03 Feb 2014 07:00 AM
RNS
Avacta Initiates Collaboration with University
28 Jan 2014 07:00 AM
RNS
Avacta Life Sciences Launches Affimers Web Site
24 Jan 2014 02:57 PM
RNS
Result of AGM
24 Jan 2014 07:00 AM
RNS
AGM Statement
20 Jan 2014 07:00 AM
RNS
Issue of Equity
13 Jan 2014 07:00 AM
RNS
Investor teach-in
23 Dec 2013 02:59 PM
RNS
Notice of AGM and Report and Accounts
23 Dec 2013 07:00 AM
RNS
Board Appointment
27 Nov 2013 10:01 AM
RNS
New Canine Lymphoma Blood Test Launched
01 Nov 2013 07:00 AM
RNS
Issue of Equity
24 Oct 2013 07:00 AM
RNS
Preliminary Results
17 Oct 2013 07:00 AM
RNS
First therapeutic licensing agreement for Affimers
26 Sep 2013 07:00 AM
RNS
Launch of Sensipod - First Point of Care Test
18 Sep 2013 07:00 AM
RNS
Issue of Equity and Notice of Preliminary Results
16 Sep 2013 07:00 AM
RNS
New Head of R&D Joins Avacta
02 Sep 2013 05:47 PM
RNS
TR-1 Notification of Major Interest in Shares
29 Aug 2013 07:00 AM
RNS
Pre-close trading update
28 Aug 2013 07:00 AM
RNS
Issue of Equity
09 Aug 2013 08:35 AM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 05:51 PM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 04:31 PM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 04:30 PM
RNS
TR-1: Notification of Major Interest in Shares
07 Aug 2013 04:00 PM
RNS
TR-1: Notification of Major Interest in Shares

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100